Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study

BACKGROUND: Although immune checkpoint inhibitor (ICI) therapy has improved the prognosis of unresectable hepatocellular carcinoma (HCC), it has also resulted in unique immune-related adverse events (irAEs). The relationship between irAE and treatment outcomes in ICI-treated unresectable HCC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiang-Min, Xiong, Hui-Fang, Chen, Xiao-Ping, Zhang, Zhi-Wei, Zhu, Li-Ping, Wu, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134210/
https://www.ncbi.nlm.nih.gov/pubmed/37123056
http://dx.doi.org/10.4251/wjgo.v15.i4.689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134210/
https://www.ncbi.nlm.nih.gov/pubmed/37123056
http://dx.doi.org/10.4251/wjgo.v15.i4.689

Ejemplares similares